Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Abeona Therapeutics (ABEO) EBITDA Margin (2016 - 2025)

Abeona Therapeutics has reported EBITDA Margin over the past 13 years, most recently at 375.13% for Q4 2025.

  • Quarterly results put EBITDA Margin at 375.13% for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was 1225.31% (changed N/A YoY), and the annual figure for FY2025 was 1225.31%, changed.
  • EBITDA Margin for Q4 2025 was 375.13% at Abeona Therapeutics, down from 27213.75% in the prior quarter.
  • Over the last five years, EBITDA Margin for ABEO hit a ceiling of 97293.75% in Q4 2021 and a floor of 10597.06% in Q4 2022.
  • Median EBITDA Margin over the past 4 years was 319.47% (2021), compared with a mean of 10908.16%.
  • Biggest five-year swings in EBITDA Margin: skyrocketed 9782225bps in 2021 and later tumbled -10789081bps in 2022.
  • Abeona Therapeutics' EBITDA Margin stood at 97293.75% in 2021, then tumbled by -111bps to 10597.06% in 2022, then skyrocketed by 96bps to 476.69% in 2023, then increased by 21bps to 375.13% in 2025.
  • The last three reported values for EBITDA Margin were 375.13% (Q4 2025), 27213.75% (Q2 2025), and 476.69% (Q2 2023) per Business Quant data.